López SN

Language: Spanish
References: 19
Page: 75-78
PDF size: 83.58 Kb.

Text Extraction

No abstract

REFERENCES

1. Hall JE. Chapter 32 Red blood cells, anemia and polycithemia. Guyton and Hall Phsiology Review, Ed. Elsevier Saunders, 2006: 419-28.

2. Andrews NC. Disorders of iron metabolism. NEJM 1999; 341: 1986-95.

3. Brittenham GM, Badman DG. Noninvasive measurement of iron: report of an NIDDK workshop. Blood 2003; 101: 15-9.

4. Hershko C, Link G, Cabantchik I. Pathophydiology of iron overload. Ann N Y Acad Sci 1998; 850: 191-201.

5. Piperno A. Classification an diagnosis iron overload. Hematological 1998; 83: 447-55.

6. Porter J. Concepts and goals in the management of transfusional iron overlosad. American Journal of Hematology 2007: 82.

7. Hershko C. Iron loading and its clinical implications. American Journal of Hematology, 2007.

8. Schafer AI, Cheron RG, Dluhy R et al. Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med 1981; 304: 319-24.

9. Zurlo MG, De Stefano P, Borgna-Pignatti C et al. Survival and causes of death in thalassaemia major. Lancet 1989; 2: 27-30.

10. Borgna-Pignatti C, Rugolotto S, De Stefano P et al. Survival and disease complications in thalassemia major. Ann N Y Acad Sci 1998; 850: 227-31.

11. Aldouri MA, Wonke B, Hoffbrand AV et al. High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation. Acta Haematol 1990; 84: 113-7.

12. Aessopos A, Farmakis D, Karagiorga M et al. Cardiac involvement in thalassemia intermedia: a multicenter study. Blood 2001; 97: 3411-6.

13. Batra AS, Acherman RJ, Wong WY et al. Cardiac abnormalities in children with sickle cell anemia. Am J Hematol 2002; 70: 306-12.

14. The Management of Sickle Cell Disease. U.S. Department of Health and Human Services. Division of Blood Disorders and Resources. NIH publication No. 04-2117.

15. Kushner JS, Porter JP, Olivieri NF. Secondary Iron Overload, Hematology 2001: 47-61.

16. Kwiatkowski JJ, Cohen AR. Iron chelation therapy in sickle-cell disease and other transfusion-dependent anemia’s. Hematol Oncol Clin N Am 2004; 18: 1355-1377.

17. Maggio A et al. Blood Cells Mol Dis 2002; 28 (2): 196-208.

18. Choudry VP, Naithani R. Current status of iron overload and chelation with deferasirox. Indian J Ped 2007; 74: 759-764.

19. Cohen AR. New advances in iron chelation therapy. In Hematology. American Society of Hematology 2006: 42-47.